Meso Scale Diagnostics
Meso Scale Diagnostics is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer
Sponsor Ideaya Biosciences Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Two-part, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients with Moderate-to-severe Atopic Dermatitis
Sponsor Apogee Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Early Alzheimer’s Disease
Sponsor Acumen Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Global, Randomized, Modified Double-Blind, Placebo‑Controlled, Study to Evaluate the Efficacy, Immunogenicity, and Safety of IVX-A12, a Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Virus-Like Particle (VLP) Vaccine in Adults 60 Years of Age and Older.
Sponsor AstraZeneca AB
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 2, Safety and Efficacy Study of PRT3789 in Combination with Pembrolizumab in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
Sponsor Prelude Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Long-term Extension Study to Evaluate the Safety, Tolerability, and Efficacy of AL002 in Participants with Alzheimer's Disease
Sponsor Alector LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Multicenter, Open-Label Phase Followed by a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children with Hypochondroplasia: ACCEL 2/3
Sponsor Qed Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomised, Observer-Blind Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of a Group B Streptococcus Vaccine (GBS-NN/NN-2) when 1 Dose is Administered Concomitantly with the TDaP Vaccine in Healthy Non-pregnant Women 18 to 49 years of age Compared to when Each Vaccine is Administered Alone
Sponsor Minervax ApS
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Meso Scale Diagnostics?
The 2026-10-09 snapshot links Meso Scale Diagnostics to 8 distinct CTIS trials. Recorded services include Laboratory services, CXM Analysis, Data management, Nucleic acid samples, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Meso Scale Diagnostics?
The most frequently recorded therapeutic areas are Dermatology, Gastroenterology, Neurology, Respiratory. Recorded phases include Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Meso Scale Diagnostics conducted?
The linked trials record locations in 15 countries, including Spain, France, Germany, Poland, Belgium. These are trial locations, not confirmed office locations or countries where Meso Scale Diagnostics delivered services.
What can this page tell me about Meso Scale Diagnostics's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Meso Scale Diagnostics. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Meso Scale Diagnostics LLC